Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Mulligan

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|October 21, 2016
Modeling the chronic lymphocytic leukemia microenvironment in vitroKyle Crassini, Yandong Shen, Stephen Mulligan, et al.
Internal Medicine Journal|November 11, 2023
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemiaRoss Salvaris, Stephen Mulligan, Andrea Puig, et al.
The Australasian Journal of Dermatology|March 16, 2017
Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemiaAndrew Lee, Suneet Sandhu, Louise Imlay-Gillespie, et al.
Journal of Orthopaedic Case Reports|June 16, 2025
A Rare Case of Orf Virus Precipitating Methicillin-Resistant Staphylococcus Aureus Bacteremia Superinfection Leading to Native Hip Joint Septic ArthritisAlexander Price, Cónan Marren, Stephen Mulligan, et al.
British Journal of Haematology|July 7, 2018
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironmentKyle Crassini, Yandong Shen, Michael O'Dwyer, et al.
BMC Cancer|April 16, 2025
Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trialStephane Kroudia Wasse, Sandrine Tienhan Dabakuyo-Yonli, David Gottlieb, et al.
Plos Neglected Tropical Diseases|June 13, 2020
Environmental influences on Aedes aegypti catches in Biogents Sentinel traps during a Californian "rear and release" program: Implications for designing surveillance programsKyran M Staunton, Jacob E Crawford, Devon Cornel, et al.
F1000Research|September 8, 2016
Surveillance, insecticide resistance and control of an invasive Aedes aegypti (Diptera: Culicidae) population in CaliforniaAnthony J Cornel, Jodi Holeman, Catelyn C Nieman, et al.
International Journal of Molecular Sciences|August 28, 2025
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and MyelomaElizabeth Hughes, Sue Latham, Bryone Kuss, et al.
Internal Medicine Journal|July 8, 2024
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern eraDiva Baggio, Eliza Chung, Cameron Wellard, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|October 21, 2016
Modeling the chronic lymphocytic leukemia microenvironment in vitroKyle Crassini, Yandong Shen, Stephen Mulligan, et al.
Internal Medicine Journal|November 11, 2023
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemiaRoss Salvaris, Stephen Mulligan, Andrea Puig, et al.
The Australasian Journal of Dermatology|March 16, 2017
Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemiaAndrew Lee, Suneet Sandhu, Louise Imlay-Gillespie, et al.
Journal of Orthopaedic Case Reports|June 16, 2025
A Rare Case of Orf Virus Precipitating Methicillin-Resistant Staphylococcus Aureus Bacteremia Superinfection Leading to Native Hip Joint Septic ArthritisAlexander Price, Cónan Marren, Stephen Mulligan, et al.
British Journal of Haematology|July 7, 2018
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironmentKyle Crassini, Yandong Shen, Michael O'Dwyer, et al.
BMC Cancer|April 16, 2025
Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trialStephane Kroudia Wasse, Sandrine Tienhan Dabakuyo-Yonli, David Gottlieb, et al.
Plos Neglected Tropical Diseases|June 13, 2020
Environmental influences on Aedes aegypti catches in Biogents Sentinel traps during a Californian "rear and release" program: Implications for designing surveillance programsKyran M Staunton, Jacob E Crawford, Devon Cornel, et al.
F1000Research|September 8, 2016
Surveillance, insecticide resistance and control of an invasive Aedes aegypti (Diptera: Culicidae) population in CaliforniaAnthony J Cornel, Jodi Holeman, Catelyn C Nieman, et al.
International Journal of Molecular Sciences|August 28, 2025
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and MyelomaElizabeth Hughes, Sue Latham, Bryone Kuss, et al.
Internal Medicine Journal|July 8, 2024
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern eraDiva Baggio, Eliza Chung, Cameron Wellard, et al.
Pageof 3